Physician profile
Sanjay Batta
NPI 1669693552
$28,124.50
in general payments reported to CMS, 2019-2025
46 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,502 · 2020: $6,724 · 2021: $4,756 · 2022: $2,011 · 2023: $2,035 · 2024: $2,197 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,132.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $6,280.67 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $5,435.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $3,094.92 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,510.79 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $1,719.11 | 2019-2025 | Camzyos, Eliquis |
| Biohaven Pharmaceuticals, INC. | $1,225.28 | 2021 | |
| Novo Nordisk INC | $1,177.86 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $958.55 | 2019-2025 | Jardiance |
| Amgen INC. | $932.14 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $712.74 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $606.40 | 2019-2023 | |
| Abbott Laboratories | $602.12 | 2021-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Exact Sciences Corporation | $380.96 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Abbvie INC. | $309.42 | 2019-2024 | |
| Allergan, INC. | $305.00 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Batta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.